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The brain-gut-microbiota axis is viewed by some as a major paradigm shift in mental illness 
with the potential for the development of entirely novel therapies, while others have 
expressed scepticism regarding the approach(Dinan and Cryan 2017).  What is now 
abundantly clear is the fact that the gut microbiota is a major source of metabolic activity and 
that such activity influencing all organs, including the brain.  The routes of communication 
between the gut microbes and the brain have been partially established in rodents but far less 
is known about such routes in humans(Dinan, Cryan et al. 2018).  The vagus nerve, short 
chain fatty acids, tryptophan and cytokines have all been implicated in gut to brain 
connectivity.  That altered gut microbes (dysbiosis) might negatively impact gut to brain 
signalling in disorders such as depression is becoming an important field of study.  The study 
from Jiang and colleagues (Jiang, Ling et al. 2015), winner of the 2019 BBI Impact Award, is 
a landmark in this respect, as almost all of the studies prior to this were preclinical in nature. 
The slightly earlier study of Naseribafrouei et al recruited thirty-seven patients with 
depression and eighteen non-depressed controls(Naseribafrouei, Hestad et al. 2014) .  They 
found no differences in diversity between the two groups, though they did report several 
correlations between depression and the faecal microbiota.  The study is limited by a small 
sample size, especially of healthy controls. The Jiang et al paper had been widely cited 
because it was the first publication to report an altered gut microbiota in depressed patients.  
The dysbiosis detected was an increase in microbial diversity in acutely depressed patients, 
which was an unexpected finding.  The general assumption has been that increased diversity 
is a positive health benefit, a fact which is especially true in the elderly where a lack of 
diversity is associated with frailty.  Interestingly, such changes were not seen in those 
depressives who had responded to treatment.  This may be explained by the fact that 
psychotropic medications have a major impact on the gut microbiota(Cussotto, Strain et al. 
2018).  In a subsequent similar study, the APC group also found a dysbiosis in depression, 
but in contrast the alteration consisted of decreased microbial diversity (Kelly, Borre et al. 
2016). When rodents underwent a faecal microbiota transplant (FMT) from depressed 
patients they developed an anhedonic behavioural phenotype with increases in acute phase 
proteins and altered tryptophan metabolism.  Given the increasing use in gastroenterology of 
FMT as a treatment for C. difficile infection, the studies lend support for the view that 
psychiatric profiling of the faecal donor is essential. 
Insert Fig 1 here 
The largest study to date comes from the Jeroen Raes group who studied the relationship 
between gut bacteria and quality of life and depression(Valles-Colomer, Falony et al. 2019). 
They combined faecal microbiome data with general practitioner diagnoses of depression 
from 1,054 individuals enrolled in the Flemish Gut Flora Project. They found specific groups 
of bacteria that positively or negatively correlated with quality of life; two bacterial genera, 
Coprococcus and Dialister, were depleted in patients with depression, whether or not they 
were taking antidepressants.  Butyrate-producing bacteria were consistently associated with 
higher quality of life measures.  The findings were replicated in an independent cohort of 
1,063 individuals from the Dutch LifeLinesDEEP cohort and in a sample of clinically 
depressed patients at the University Hospitals Leuven, Belgium.  The results provide the first 
population based evidence for microbiome links with mental health.  The microbiology 
seems to have been conducted to a very high standard, but the study would be of greater 
importance overall if the phenotyping was more precise and if depression was the primary 
clinical measure, rather than a combination of quality of life and depression, variables that are 
related but clearly not equivalent.  Despite this reservation the study is a welcome addition to 
the literature. 
If there is a gut dysbiosis in depression, how does this result in the inflammatory phenotype 
observed in many patients?  The answer is simple, we do not know how this comes about.  
The preclinical findings indicate that the altered microbiota induced by stress is associated 
with changes in gut permeability which is referred to as a ‘leaky gut’(Ohlsson, Gustafsson et 
al. 2019).  If this is the situation in depression, molecules which should not enter the 
bloodstream such as lipopolysaccharide are enabled to do, triggering an inflammatory 
response via toll-like receptors with an increase in pro-inflammatory cytokines release. 
The Jiang et al study is an important watershed that has raised enthusiasm for the view that 
the gut microbiota might be an integral part of the pathophysiology of depression and as such 
a potential therapeutic target.  The possible interventions might include dietary manipulation, 
use of beneficial microbes (psychobiotics), use of prebiotics to stimulate growth of beneficial 
microbes and possibly the use of targeted antibiotics.  Under normal physiological 
circumstances diet is the most important manipulator of the gut microbiota and it is 
incumbent upon psychiatrists to provide appropriate dietary advice for their patients, an 
aspect of therapeutic care which is frequently neglected.  There is an alarmingly high 
correlation between poor diet and mental health issues and the gut microbiota is an important 
variable in this relationship. Clinicians also need to be cognizant of the fact that our current 
psychotropics impact the gut microbiota with potential significant side-effects, take for 
example the effects of atypical antipsychotics on the gut microbiota and the major problem of 
weight gain in many patients(Davey, Cotter et al. 2013). 
While enormous progress has been made in this field over the past decade, we patiently await 
definitive developments that will impact patient care.  Hopefully, the field will not meet the 
fate of the Beckett characters in Waiting for Godot!  
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Fig. 1 shows the routes of communication between gut microbes and brain together with the 
channels from brain to gut.  Research to date supports the view of a gut dysbiosis in depression. 
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